1
|
Yahya MS, Abdel Hameed FF, Radwan NH, Abdelgawad IA, Soliman AF. Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients. Asian Pac J Cancer Prev 2024; 25:709-717. [PMID: 38415559 PMCID: PMC11077105 DOI: 10.31557/apjcp.2024.25.2.709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Indexed: 02/29/2024] Open
Abstract
OBJECTIVE This study aimed to assess the relative gene expression level of transforming growth factor-β1 (TGFB1) and haptoglobin (HP) in the peripheral blood of prostate cancer (PCa) patients and evaluate their diagnostic ability. METHODS A total of 125 participants were enrolled in the present study. Among them, 75 PCa patients, 25 benign prostatic hyperplasia (BPH) patients, and 25 healthy volunteers served as the control group. The relative TGFB1 and HP gene expression level was quantified using real-time polymerase chain reaction. Further, free and total PSA levels were determined using electrochemiluminescence assays. RESULTS TGFB1 was significantly over-expressed, whereas HP was significantly downregulated in the peripheral blood of PCa patients compared to BPH and control groups (p-value ranges from 0.034 to <0.001). Moreover, the high expression level of TGFB1 was associated with an increased risk of PCa development with OR=1.412 (95%CI: 1.081-1.869, p= 0.012). TGFB1 and HP relative expression levels had lower diagnostic performance to differentiate PCa from normal and BPH individuals compared to PSA, however, the combination of the tested parameters improved the diagnostic efficacy. CONCLUSIONS TGFB1 and HP relative expression have moderate diagnostic efficacy in discriminating patients with PCa from BPH and healthy subjects. Furthermore, over-expression of TGFB1 may contribute to the pathogenesis of PCa.
Collapse
Affiliation(s)
- Mohammed S Yahya
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt
| | - Fatma F Abdel Hameed
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt
| | - Noha H Radwan
- Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
| | - Iman A Abdelgawad
- Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
| | - Ahmed F Soliman
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt
| |
Collapse
|
2
|
Lukianova N, Zadvornyi Т, Borikun Т, Mushii О, Pavlova А, Tymoshenko А, Stakhovskyi Е, Vitruk I, Сhekhun V. SIGNIFICANCE OF OSTEOPONTIN FOR PREDICTING AGGRESSIVENESS OF PROSTATE CANCER. Exp Oncol 2023; 45:312-321. [PMID: 38186024 DOI: 10.15407/exp-oncology.2023.03.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Indexed: 01/09/2024]
Abstract
BACKGROUND Effective prediction of the course of prostate cancer (PCa) and the stratification of treatment tactics largely depend on the use of prognostic markers that reflect the molecular and biological features of tumors. In view of the important role of matricellular proteins in the modulation of the growing tumor and metastasis of the hormone-dependent neoplasms, the aim of the work was to study the expression of osteopontin (OPN) at the protein and mRNA levels in the PCa tissue in order to assess the significance of this protein for predicting the aggressiveness of PCa. MATERIALS AND METHODS The work is based on the analysis of the results of the examination and treatment of 83 patients with PCa of stages II-IV. The study of OPN expression at the level of mRNA and protein in the PCa tissue was carried out using methods of the real time polymerase chain reaction and immunohistochemistry, respectively. RESULTS The OPN expression in the PCa tissue was 1.6 times (p < 0.05) higher in patients with regional lymph node metastases compared to patients without metastases. In patients with a Gleason score of < 7, the OPN expression in the tumor tissue was 1.4 times lower (p < 0.05) than in patients with poorly differentiated PCa. In patients with a high risk of tumor progression, the OPN expression level was 1.4 and 2.1 times higher (p < 0.05) compared to patients with a moderate and low risk of PCa progression. The patients with a high OPN expression level in the PCa tissue had significantly decreased 2-year recurrence-free survival rate (by 25%). CONCLUSIONS The obtained results indicate the expediency of using OPN expression indicators in the tumor tissue to predict the PCa aggressiveness and assess the risk of its recurrence.
Collapse
Affiliation(s)
- N Lukianova
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - Т Zadvornyi
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - Т Borikun
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - О Mushii
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - А Pavlova
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - А Tymoshenko
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - Е Stakhovskyi
- The State Non-Profit Enterprise "National Cancer Institute" of the Ministry of Health of Ukraine, Kyiv, Ukraine
| | - I Vitruk
- The State Non-Profit Enterprise "National Cancer Institute" of the Ministry of Health of Ukraine, Kyiv, Ukraine
| | - V Сhekhun
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| |
Collapse
|
3
|
Maiti KS. Non-Invasive Disease Specific Biomarker Detection Using Infrared Spectroscopy: A Review. Molecules 2023; 28:2320. [PMID: 36903576 PMCID: PMC10005715 DOI: 10.3390/molecules28052320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/22/2023] [Accepted: 02/22/2023] [Indexed: 03/06/2023] Open
Abstract
Many life-threatening diseases remain obscure in their early disease stages. Symptoms appear only at the advanced stage when the survival rate is poor. A non-invasive diagnostic tool may be able to identify disease even at the asymptotic stage and save lives. Volatile metabolites-based diagnostics hold a lot of promise to fulfil this demand. Many experimental techniques are being developed to establish a reliable non-invasive diagnostic tool; however, none of them are yet able to fulfil clinicians' demands. Infrared spectroscopy-based gaseous biofluid analysis demonstrated promising results to fulfil clinicians' expectations. The recent development of the standard operating procedure (SOP), sample measurement, and data analysis techniques for infrared spectroscopy are summarized in this review article. It has also outlined the applicability of infrared spectroscopy to identify the specific biomarkers for diseases such as diabetes, acute gastritis caused by bacterial infection, cerebral palsy, and prostate cancer.
Collapse
Affiliation(s)
- Kiran Sankar Maiti
- Max–Planck–Institut für Quantenoptik, Hans-Kopfermann-Straße 1, 85748 Garching, Germany; ; Tel.: +49-289-14054
- Lehrstuhl für Experimental Physik, Ludwig-Maximilians-Universität München, Am Coulombwall 1, 85748 Garching, Germany
- Laser-Forschungslabor, Klinikum der Universität München, Fraunhoferstrasse 20, 82152 Planegg, Germany
| |
Collapse
|
4
|
Sharma P, Watts A, Singh H. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC. Clin Nucl Med 2022; 47:948-953. [PMID: 35961365 DOI: 10.1097/rlu.0000000000004353] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Prostate cancer (PCa) is the most common cancer in men worldwide. Targeting prostate-specific membrane antigen (PSMA) using radiopharmaceuticals has shown promising results for PCa imaging as well as theranostics. 68 Ga-based PSMA imaging is limited by production of small quantities by generator, and it has led to quest for cyclotron produced 18 F-based PSMA ligands. In the current study, we evaluated the biodistribution and internal dosimetry of 18 F-PSMA-1007 and compared it with 68 Ga-PSMA-11-HBED-CC. MATERIALS AND METHODS A total of 8 patients with histopathologically proven PCa were included in the study, of whom 4 patients underwent 18 F-PSMA-1007, and the other 4 patients underwent 68 Ga-PSMA-11-HBED-CC PET/CT. The biodistribution of both tracers was quantified for different organs by computing SUVs. All the patients underwent 5-point serial imaging to compute equivalent dose to essential organs and whole-body effective dose using OLINDA-based dosimetry. RESULTS The radiotracer uptake in brain, lacrimal gland, salivary gland, heart, lung, liver, gallbladder, spleen, pancreas, intestine, gluteal muscle, and bone marrow were found to be higher in 18 F-PSMA-1007 PET as compared with 68 Ga PSMA-11 PET. Kidney and urinary bladder showed higher SUV value on 68 Ga-PSMA-11-HBED-CC as compared with 18 F-PSMA-1007.The whole-body effective dose from 18 F-PSMA-1007 (1.46E-02 mSv/MBq) was higher than 68 Ga-PSMA-11-HBED-CC (1.03E-02 mSv/MBq). The highest mean equivalent dose from 18 F-PSMA-1007 was observed in the kidneys (1.48E-01 mGy/MBq), followed by spleen (mean, 1.06E-01 mGy/MBq) and liver (6.80E-02 mGy/MBq), whereas 68 Ga-PSMA-11-HBED-CC equivalent dose was maximum in the kidneys (2.13E-01 mGy/MBq), followed by liver (3.03E-02 mGy/MBq), spleen (2.90E-02 mGy/MBq), adrenals (2.67E-02 mGy/MBq), and urinary bladder (1.89E-02 mGy/MBq). CONCLUSION Whole-body effective dose from 18 F-PSMA-1007 is higher compared with 68 Ga-PSMA-11-HBED-CC. 18 F-PSMA-1007 shows lesser urinary bladder clearance compared with 68 Ga-PSMA-11-HBED-CC, which can allow better interpretation of prostatic bed without significant radioactive urine interference. 18 F-PSMA-1007 is a cyclotron-produced alternative to generator-produced 68 Ga-PSMA-11-HBED-CC and can emerge as a good diagnostic surrogate for patients planned for 177 Lu-PSMA-617 therapy.
Collapse
Affiliation(s)
- Priya Sharma
- From the Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | | |
Collapse
|
5
|
Messina M, Duncan A, Messina V, Lynch H, Kiel J, Erdman JW. The health effects of soy: A reference guide for health professionals. Front Nutr 2022; 9:970364. [PMID: 36034914 PMCID: PMC9410752 DOI: 10.3389/fnut.2022.970364] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 07/25/2022] [Indexed: 11/22/2022] Open
Abstract
Soy is a hotly debated and widely discussed topic in the field of nutrition. However, health practitioners may be ill-equipped to counsel clients and patients about the use of soyfoods because of the enormous, and often contradictory, amount of research that has been published over the past 30 years. As interest in plant-based diets increases, there will be increased pressure for practitioners to gain a working knowledge of this area. The purpose of this review is to provide concise literature summaries (400-500 words) along with a short perspective on the current state of knowledge of a wide range of topics related to soy, from the cholesterol-lowering effects of soy protein to the impact of isoflavones on breast cancer risk. In addition to the literature summaries, general background information on soyfoods, soy protein, and isoflavones is provided. This analysis can serve as a tool for health professionals to be used when discussing soyfoods with their clients and patients.
Collapse
Affiliation(s)
- Mark Messina
- Soy Nutrition Institute Global, Washington, DC, United States
| | - Alison Duncan
- Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada
| | | | - Heidi Lynch
- Kinesiology Department, Point Loma Nazarene University, San Diego, CA, United States
| | - Jessica Kiel
- Scientific and Clinical Affairs, Medifast Inc., Baltimore, MD, United States
| | - John W. Erdman
- Division of Nutritional Sciences and Beckman Institute, Department of Food Science and Human Nutrition, University of Illinois at Urbana/Champaign, Urbana, IL, United States
| |
Collapse
|
6
|
Hong JH, Liang ST, Wang ASS, Yeh CM, Huang HP, Sun CD, Zhang ZH, Lu SY, Chao YH, Chen CH, Pu YS. LMNB1, a potential marker for early prostate cancer progression. Am J Cancer Res 2022; 12:3390-3404. [PMID: 35968338 PMCID: PMC9360214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 06/20/2022] [Indexed: 06/15/2023] Open
Abstract
Although prostate cancer (PC) is the most common cancer among men in the Western world, there are no good biomarkers that can reliably differentiate between potentially aggressive and indolent PC. This leads to overtreatment, even for patients who can be managed conservatively. Previous studies have suggested that nuclear lamin proteins-especially lamin B1 (LMNB1)-play important roles in PC progression. However, the results of these studies are inconsistent. Here, we transfected the LMNB1 gene into the telomerase reverse transcriptase-immortalized benign prostatic epithelial cell line, EP156T to generate a LMNB1-overexpressing EP156T (LMN-EP156T) cell line with increased cellular proliferation. However, LMN-EP156T cells could neither form colonies in soft agar, nor establish subcutaneous growth or metastasis in the xenograft NOD/SCID mouse model. In addition, immunohistochemical staining of LMNB1 in PC specimens from 143 patients showed a statistically significant trend of stronger LMNB1 staining with higher Gleason scores. A univariate analysis of the clinicopathological parameters of 85 patients with PC who underwent radical prostatectomy revealed that pathological stage, resection margin, and extracapsular extension were significant predictors for biochemical recurrence (BCR). However, LMNB1 staining showed only a non-significant trend of association with BCR (high vs. low staining: hazard ratio (HR), 1.83; 95% confidence interval (CI), 0.98-3.41; P = 0.059). In multivariate analysis, only pathological stage was a significant independent predictor of BCR (pT3 vs. pT2: HR, 2.29; 95% CI, 1.18-4.43; P = 0.014). In summary, LMNB1 may play a role in the early steps of PC progression, and additional molecular alterations may be needed to confer full malignancy potential to initiated cells.
Collapse
Affiliation(s)
- Jian-Hua Hong
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
- Institute of Biomedical Engineering, National Taiwan UniversityTaipei, Taiwan
| | - Sung-Tzu Liang
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| | | | - Chia-Ming Yeh
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| | - Hsiang-Po Huang
- Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of MedicineTaipei, Taiwan
| | - Chia-Dong Sun
- Department of Pathology, National Taiwan University HospitalTaipei, Taiwan
- Department and Graduate Institute of Forensic Medicine, College of Medicine, National Taiwan UniversityTaipei, Taiwan
| | | | - Shih-Yu Lu
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| | - Yen-Hsiang Chao
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| | - Chung-Hsin Chen
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| | - Yeong-Shiau Pu
- Department of Urology, National Taiwan University HospitalTaipei, Taiwan
| |
Collapse
|
7
|
Crulhas BP, Basso CR, Castro GR, Pedrosa VA. Detection of Prostate Cancer Biomarker PCA3 by using Aptasensors. Curr Med Chem 2022; 29:5895-5902. [PMID: 35674300 DOI: 10.2174/0929867329666220607162250] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 01/02/2022] [Accepted: 03/10/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Prostate cancer cells have very high PCA3 messenger RNA levels, which turns it into one of the new biomarkers for prostate cancer prognosis and diagnosis. OBJECTIVE Our goal here is to development a new aptasensor to detect PCA3 release by cancer cell. METHODS DNA hairpin containing PCA3 aptamer was thiolated, conjugated to methylene blue (MB) redox probe and immobilized on gold electrode through self-assembly to detect label-free cancer cells. RESULTS Our data have evidenced stable and sensitive sensor presenting wide linear detection range (0-150 ng/mL). In addition, monitoring PCA3 released by a different type of prostate cells can provide in-depth knowledge about prostate cancer dynamics; therefore, it is a powerful platform for earlier clinical diagnostic. The released PCA3 can vary depending on the type of adopted prostate cells. CONCLUSION PCA3 release was monitored in a group of cells for 2 h; it showed significantly higher expression in both LNCaP and PC-3 cells. This strategy provides unique and simple methodology to achieve more sensitive and specific PCA3 detection; thus, it emerged as promising tool for early cost-effective diagnosis.
Collapse
Affiliation(s)
- Bruno P Crulhas
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP, Botucatu, SP, Brazil
| | - Caroline R Basso
- Department of Chemistry and Biochemistry, Department of Chemistry and Biochemistry,, UNESP, Botucatu, SP, Brazil
| | - Gustavo R Castro
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP, Botucatu, SP, Brazil
| | - Valber A Pedrosa
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP, Botucatu, SP, Brazil
| |
Collapse
|
8
|
Nerli RB, Ghagane SC, Bidi SR, Thakur ML, Gomella L. Voided urine test to diagnose prostate cancer: Preliminary report. Cytojournal 2021; 18:26. [PMID: 34754324 PMCID: PMC8571200 DOI: 10.25259/cytojournal_76_2020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 05/28/2021] [Indexed: 11/04/2022] Open
Abstract
Objectives Prostate cancer (PCa) is a common malignancy affecting elderly male. At present, PCa is estimated using serum prostate-specific antigen (PSA). Prostate biopsy remains the gold standard to confirm the diagnosis of PCa. In this preliminary study, we have assessed the feasibility of detecting PCa using voided urine by targeting the genomic vasoactive intestinal peptide receptor (VPAC) expressed on malignant PCa cells. Material and Methods Patients ≥40 years old, with no lower urinary tract symptoms (LUTS) and serum PSA levels of <1.6 ng/mL formed the control group and patients ≥40 years old, with LUTS and serum PSA >2.6 ng/ mL formed the study group. Patients were advised to give the first 50 mL of voided urine sample for the detection of malignant markers by targeting the VPAC. The results of histopathological studies were then compared to the results of urine biomarker. Results The study revealed absence of malignant markers in 75 patients (control group). In the study group, all the 33 patients with adenocarcinoma were positive for malignant markers in the biomarker study and absence of malignant markers in the 32 patients with benign histology. The results of the biomarker studies and histopathology were consistent with each other. Conclusion This preliminary study validates our belief that patients with PCa do shed malignant cells in the urine which can be identified by targeting the VPAC. The investigation is easy and our data appear to be highly encouraging and further serve as a simple, reliable, and a non-invasive tool in the detection of PCa.
Collapse
Affiliation(s)
- R B Nerli
- Department of Urology, Division of Urologic-Oncology, JN Medical College, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi, Karnataka, India.,Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
| | - Shridhar C Ghagane
- Department of Urology, Division of Urologic-Oncology, JN Medical College, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi, Karnataka, India.,Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
| | - Saziya R Bidi
- Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
| | - Madhukar L Thakur
- Department of Urology, Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.,Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
| | - Leonard Gomella
- Department of Urology, Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.,Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.,The Sidney Kimmel Cancer Centre, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
| |
Collapse
|
9
|
Pekarek L, Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon MA, Acero J, Ruiz-Llorente L, García-Honduvilla N, Albillos A, Buján J, Alvarez-Mon M, Guijarro LG, Ortega MA. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives. Oncol Lett 2021; 22:809. [PMID: 34630716 PMCID: PMC8490971 DOI: 10.3892/ol.2021.13070] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 09/03/2021] [Indexed: 12/13/2022] Open
Abstract
Pancreatic cancer has a dire prognosis and will represent the second leading cause of cancer death in the next 10 years. The multifactorial approach represents one of the main issues in controlling the extension of this neoplasm. In recent years, the characteristics of the tumor microenvironment, metastasis mechanisms and the relationship between immune system and neoplastic cells have been described, which has made it possible to understand the pathophysiology of pancreatic adenocarcinoma. Currently, there is a failure to provide an effective preventive method or early detection, so patients present with an advanced stage at the time of diagnosis. Despite numerous efforts, little progress has been made in clinical outcome and in improving survival in long term. Therefore, in the recent years, diverse diagnostic tests, treatments and possible approaches have been developed in the fields of radiotherapy, chemotherapy and surgery to find a combination of them that improves life expectancy in patients diagnosed with pancreatic cancer. At the moment, numerous clinical trials are being conducted to evaluate preventive diagnostic procedures such as serological markers or perfecting available imaging tests. On the other hand, implementation of immunotherapy is being studied in a neoplasm that has lagged in the application of this procedure since present possible treatments do not substantially improve quality of life. Therefore, the purpose of our study is to summarize the main progresses that have been made in the diagnosis, treatment and screening of this disease, explaining the limitations that have been observed and analyzing future prospects in the management of this illness.
Collapse
Affiliation(s)
- Leonel Pekarek
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Oncology Service, Guadalajara University Hospital, 19002 Guadalajara, Spain
| | - Oscar Fraile-Martinez
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
| | - Cielo Garcia-Montero
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
| | - Miguel A. Alvarez-Mon
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
| | - Julio Acero
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
| | - Lidia Ruiz-Llorente
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Unit of Biochemistry and Molecular Biology, Department of System Biology, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
| | - Natalio García-Honduvilla
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
| | - Agustin Albillos
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Department of Gastroenterology and Hepatology, Ramón y Cajal University Hospital, University of Alcalá, Ramón y Cajal Institute for Health Research, 28034 Madrid, Spain
- Biomedical Research Networking Center of Hepatic and Digestive Diseases, Institute of Health Carlos III, 28034 Madrid, Spain
| | - Julia Buján
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
| | - Melchor Alvarez-Mon
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Biomedical Research Networking Center of Hepatic and Digestive Diseases, Institute of Health Carlos III, 28034 Madrid, Spain
- Immune System Diseases-Rheumatology, Oncology Service and Internal Medicine, Prince of Asturias University Hospital, Alcala de Henares, 28806 Madrid, Spain
| | - Luis G. Guijarro
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Unit of Biochemistry and Molecular Biology, Department of System Biology, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Immune System Diseases-Rheumatology, Oncology Service and Internal Medicine, Prince of Asturias University Hospital, Alcala de Henares, 28806 Madrid, Spain
| | - Miguel A. Ortega
- Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain
- Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain
- Cancer Registry and Pathology Department, Prince of Asturias University Hospital, Alcala de Henares, 28806 Madrid, Spain
| |
Collapse
|
10
|
Abd Rahman SF, Md Arshad MK, Gopinath SCB, Fathil MFM, Sarry F, Ibau C. Glycosylated biomarker sensors: advancements in prostate cancer diagnosis. Chem Commun (Camb) 2021; 57:9640-9655. [PMID: 34473143 DOI: 10.1039/d1cc03080a] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Prostate cancer is currently diagnosed using the conventional gold standard methods using prostate-specific antigen (PSA) as the selective biomarker. However, lack of precision in PSA screening has resulted in needless biopsies and delays the treatment of potentially fatal prostate cancer. Thus, identification of glycans as novel biomarkers for the early detection of prostate cancer has attracted considerable attention due to their reliable diagnostic platform compared with the current PSA systems. Therefore, biosensing technologies that provide point-of-care diagnostics have demonstrated the ability to detect various analytes, including glycosylated micro- and macro-molecules, thereby enabling versatile detection methodologies. This highlight article discusses recent advances in the biosensor-based detection of prostate cancer glycan biomarkers and the innovative strategies for the conjugation of nanomaterials adapted to biosensing platforms. Finally, the article is concluded with prospects and challenges of prostate cancer biosensors and recommendations to overcome the issues associated with prostate cancer diagnosis.
Collapse
Affiliation(s)
- Siti Fatimah Abd Rahman
- Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, 01000 Kangar, Perlis, Malaysia.
| | - Mohd Khairuddin Md Arshad
- Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, 01000 Kangar, Perlis, Malaysia. .,Faculty of Electronic Engineering Technology, Universiti Malaysia Perlis, 02600 Arau, Perlis, Malaysia
| | - Subash C B Gopinath
- Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, 01000 Kangar, Perlis, Malaysia. .,Faculty of Chemical Engineering Technology, Universiti Malaysia Perlis, 02600 Arau, Perlis, Malaysia
| | | | - Frédéric Sarry
- Université de Lorraine, CNRS, IJL, F-54000 Nancy, France
| | - Conlathan Ibau
- Institute of Nano Optoelectronics Research and Technology, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
| |
Collapse
|
11
|
Maiti KS, Fill E, Strittmatter F, Volz Y, Sroka R, Apolonski A. Towards reliable diagnostics of prostate cancer via breath. Sci Rep 2021; 11:18381. [PMID: 34526529 PMCID: PMC8443711 DOI: 10.1038/s41598-021-96845-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 08/17/2021] [Indexed: 11/30/2022] Open
Abstract
Early detection of cancer is a key ingredient for saving many lives. Unfortunately, cancers of the urogenital system are difficult to detect at early stage. The existing noninvasive diagnostics of prostate cancer (PCa) suffer from low accuracy (< 70%) even at advanced stages. In an attempt to improve the accuracy, a small breath study of 63 volunteers representing three groups: (1) of 19 healthy, (2) 28 with PCa, (3) with 8 kidney cancer (KC) and 8 bladder cancer (BC) was performed. Ultrabroadband mid-infrared Fourier absorption spectroscopy revealed eight spectral ranges (SRs) that differentiate the groups. The resulting accuracies of supervised analyses exceeded 95% for four SRs in distinguishing (1) vs (2), three for (1) vs (3) and four SRs for (1) vs (2) + (3). The SRs were then attributed to volatile metabolites. Their origin and involvement in urogenital carcinogenesis are discussed.
Collapse
Affiliation(s)
- K S Maiti
- Lehrstuhl für Experimental Physik, Ludwig-Maximilians-Universität München, Am Coulombwall 1, 85748, Garching, Germany.,Max-Planck-Institut für Quantenoptik, Hans-Kopfermann-Strasse 1, 85748, Garching, Germany
| | - E Fill
- Max-Planck-Institut für Quantenoptik, Hans-Kopfermann-Strasse 1, 85748, Garching, Germany
| | - F Strittmatter
- Urologische Klinik und Poliklinik des Klinikums der Ludwig-Maximilians-Universität München in Grosshadern, 81377, Munich, Germany
| | - Y Volz
- Urologische Klinik und Poliklinik des Klinikums der Ludwig-Maximilians-Universität München in Grosshadern, 81377, Munich, Germany
| | - R Sroka
- Urologische Klinik und Poliklinik des Klinikums der Ludwig-Maximilians-Universität München in Grosshadern, 81377, Munich, Germany.,Laser-Forschungslabor, LIFE Center, University Hospital, LMU Munich, 82152, Planegg, Germany
| | - A Apolonski
- Lehrstuhl für Experimental Physik, Ludwig-Maximilians-Universität München, Am Coulombwall 1, 85748, Garching, Germany. .,Max-Planck-Institut für Quantenoptik, Hans-Kopfermann-Strasse 1, 85748, Garching, Germany. .,Laser-Forschungslabor, LIFE Center, University Hospital, LMU Munich, 82152, Planegg, Germany. .,Novosibirsk State University, 630090, Novosibirsk, Russia. .,Institute of Automation and Electrometry SB RAS, 630090, Novosibirsk, Russia.
| |
Collapse
|
12
|
Multiplexed Prostate Cancer Companion Diagnostic Devices. SENSORS 2021; 21:s21155023. [PMID: 34372259 PMCID: PMC8347987 DOI: 10.3390/s21155023] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 07/19/2021] [Accepted: 07/21/2021] [Indexed: 12/17/2022]
Abstract
Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay (ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the required sample volume, in the complexity of the analytical procedures, and in adding to the cost. Using companion diagnostic devices such as biosensors, which can be portable and cost-effective with multiplexing capacities, may address these limitations. This review explores recent research for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor platforms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in this review. In addition, this review discusses the importance of converting research protocols into multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a more personalized approach to PCa patients’ diagnostic, surveillance and treatment management.
Collapse
|
13
|
Olooto WE, Oyelekan AA, Adewole OO, Fajobi AO, Adedo AA, Olasimbo O. Serum gonadotropins, cortisol, PSA, and micronutrient levels among men with prostate carcinoma. AFRICAN JOURNAL OF UROLOGY 2021. [DOI: 10.1186/s12301-021-00206-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Prostate cancer (PrCa) is a malignant tumour of the prostate that has many associated risk factors. There is continuous rise in the incidence among adult blacks which is a reflection of racial differences in testosterone concentrations.
Methods
The study involves 50 PrCa patients attending or referred to two tertiary health Institutions and 25 healthy men as controls. Weight and height of participants were measured, and body mass index (BMI) was calculated. Ten millilitres of venous blood sample was collected from each participant, allowed to clot, and then centrifuged at 5000 rpm for 5 min at room temperature (22–28 °C) to obtain the serum. Serum cortisol, testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), total prostate-specific antigen (TPSA), free prostate-specific antigen (FPSA), selenium, copper, magnesium, and zinc were determined. Prostate ultrasonography and biopsy were also done for histopathological studies.
Result
From this study, a significant increase (p < 0.05) in weight, BMI, serum FPSA, TPSA, and copper; a non-significant increase (p > 0.05) in serum cortisol, testosterone; a significant decrease (p < 0.05) in serum LH, selenium, zinc, and magnesium; and a non-significant decrease (p > 0.05) in serum FSH were observed among people living with PrCa when compared to the controls. However, no significant difference (p > 0.05) was observed in the height between the two groups. Ultrasonography and histology revealed evidence of prostatitis, hypertrophy, and carcinoma among the test group.
Conclusion
It can be concluded that PrCa is associated with increase serum cortisol, testosterone, and copper; and decreased serum LH, FSH, selenium, zinc, and magnesium concentrations and combination of biochemical, ultrasonographic, and histologic features are of diagnostic importance.
Collapse
|
14
|
Bonnu CH, Ramadhani AN, Saputro RB, Sesotyosari SL, Danarto R, Astuti I, Haryana SM. The Potential of hsa-mir-106b-5p as Liquid Biomarker in Prostate Cancer Patients in Indonesia. Asian Pac J Cancer Prev 2021; 22:837-842. [PMID: 33773548 PMCID: PMC8286673 DOI: 10.31557/apjcp.2021.22.3.837] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Indexed: 11/25/2022] Open
Abstract
Purpose: This study aims to explore the potential of hsa-mir-106b-5p as a new liquid biomarker for prostate cancer sufferers in Indonesia. Methods: Analysis of hsa-mir-106b-5p expression of two tissue samples from BPH patients and two PCa patients used NanoString nCounter Expression Assay then validated by qRT-PCR using 10 patient urine samples for prostate cancer and BPH. Furthermore, analysis of the role of hsa-mir-106b-5p in prostate cancer was carried out bioinformatically. Results: The results of this study indicated that the expression of hsa-mir-106b-5p in prostate cancer tissue was 1.23 times higher than that of BPH and urine of Indonesian patients (1.72 times). Moreover, this miRNA was upregulated in prostate cancer cells compared to normal cells 1.37 times. The hsa-mir-106b-5p appeared to be involved in the development of prostate cancer through the binding of genes involved in endoplasmic reticulum stress pathways and tumor suppressor genes. Conclusion: hsa-mir-106b-5p could modulate prostate cancer by interfering with the endoplasmic reticulum stress repair pathways and decreasing the expression of tumor suppressor genes involved in many biological processes. These updates our understanding of the role of hsa-mir-106b-5p in cancer and its potential as a candidate of a biomarker for clinical diagnosis of prostate cancer.
Collapse
Affiliation(s)
- Christin H Bonnu
- Department of Biotechnology, Graduate School, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Anggia N Ramadhani
- Department of Biomedical Science., Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
| | - Ranu B Saputro
- Department of Urology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Salsabila L Sesotyosari
- Department of Biomedical Science., Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
| | - R Danarto
- Department of Urology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Indwiani Astuti
- Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Sofia M Haryana
- Department of Histology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| |
Collapse
|
15
|
Albujja MH, Vasudevan R, Alghamdi S, Pei CP, Bin Mohd Ghani KA, Ranneh Y, Ismail PB. A review of studies examining the association between genetic biomarkers (short tandem repeats and single-nucleotide polymorphisms) and risk of prostate cancer: the need for valid predictive biomarkers. Prostate Int 2020; 8:135-145. [PMID: 33425790 PMCID: PMC7767939 DOI: 10.1016/j.prnil.2019.11.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 10/22/2019] [Accepted: 11/08/2019] [Indexed: 01/22/2023] Open
Abstract
Prostate cancer (PCa) is a challenging polygenic disease because the genes that cause PCa remain largely elusive and are affected by several causal factors. Consequently, research continuously strives to identify a genetic marker which could be used as an indicator to predict the most vulnerable (i.e., predisposed) segments of the population to the disease or for the gene which may be directly responsible for PCa. To enhance the genetic etiology of PCa, this research sought to discover the key studies conducted in this field using data from the main journal publication search engines, as it was hoped that this could shed light on the main research findings from these studies, which in turn could assist in determining these genes or markers. From the research highlighted, the studies primarily used two kinds of markers: short tandem repeats or single-nucleotide polymorphisms. These markers were found to be quite prevalent in all the chromosomes within the research carried out. It also became apparent that the studies differed in both quantity and quality, as well as being conducted in a variety of societies. Links were also determined between the degree and strength of the relationship between these markers and the occurrence of the disease. From the studies identified, most recommended a larger and more diverse survey for the parameters which had not been studied before, as well as an increase in the size of the community (i.e., the population) being studied. This is an indication that work in this field is far from complete, and thus, current research remains committed toward finding genetic markers that can be used clinically for the diagnosis and screening of patients with PCa.
Collapse
Affiliation(s)
- Mohammed H. Albujja
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Malaysia
- Department of Forensic Sciences, Faculty of Criminal Justice, Naif Arab University of Security Sciences, Riyadh, Saudi Arabia
| | - Ramachandran Vasudevan
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Malaysia
- Malaysian Research Institute on Ageing (MYAGEING), Malaysia
| | - Saleh Alghamdi
- Research Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Chong P. Pei
- School of Biosciences, Faculty of Health & Medical Sciences, Taylors University, Malaysia
| | - Khairul A. Bin Mohd Ghani
- Department of Surgery, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Malaysia
| | - Yazan Ranneh
- Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Malaysia
| | - Patimah B. Ismail
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Malaysia
| |
Collapse
|
16
|
Wadaa Allah AM, Abdel Hamid FF, Soliman AF, Ibrahim N, Malash I, Abdelgawad IA. Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. TURKISH JOURNAL OF BIOCHEMISTRY 2020; 45:525-532. [DOI: 10.1515/tjb-2019-0323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/31/2024]
Abstract
Abstract
Background
Prostate cancer (PC) incidence has risen globally. As there are no current independent biomarkers with high diagnostic efficiency to detect PC, this study was performed to investigate the relative gene expression levels of E2F3 and survivin in the whole blood of PC, benign prostate hyperplasia (BPH), and normal control individuals and to explore their diagnostic value.
Material and methods
Participants of the study were divided into three groups; normal control group (n=25), BPH patients (n=25), and PC patients (n=75). The E2F3 and survivin gene expression levels were assessed using real-time qPCR in addition to the measurement of free and total levels of prostate-specific antigen (PSA) using electrochemiluminescence assays.
Results
Survivin relative gene expression was over-expressed in PC and BPH patients compared to the normal control group, whereas, E2F3 did not differ significantly among the studied groups. Compared to PSA, E2F3 and survivin mRNA expression levels had lower diagnostic efficacy to differentiate PC from normal and BPH individuals with an area under curve (AUC) of 0.471 and 0.727, respectively. Further, survivin expression level was associated with increased the risk of PC.
Conclusion
Survivin and E2F3 relative expression levels in peripheral blood had low diagnostic performance to detect PC and individuals with high survivin expression levels may have higher risk to develop PC.
Collapse
Affiliation(s)
- Ahmed M. Wadaa Allah
- Biochemistry Department, Faculty of Science, Ain Shams University , Cairo , Egypt
| | - Fatma F. Abdel Hamid
- Biochemistry Department, Faculty of Science, Ain Shams University , Cairo , Egypt
| | - Ahmed F. Soliman
- Biochemistry Department, Faculty of Science, Ain Shams University , Cairo , Egypt
| | - Noha Ibrahim
- Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University , Cairo , Egypt
| | - Ibrahim Malash
- Medical Oncology Department, National Cancer Institute, Cairo University , Cairo , Egypt
| | - Iman A. Abdelgawad
- Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University , Cairo , Egypt
| |
Collapse
|
17
|
Huaman J, Ogunwobi OO. Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells 2020; 9:cells9071594. [PMID: 32630254 PMCID: PMC7408126 DOI: 10.3390/cells9071594] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 06/27/2020] [Accepted: 06/30/2020] [Indexed: 01/16/2023] Open
Abstract
Fibronectin (FN1) is an extracellular matrix protein gaining increasing attention for its multifaceted roles in cancer progression. Using our recently established circulating tumor cell (CTC) lines, we had demonstrated increased FN1 expression and enhanced migration in CTC lines, in comparison to primary tumor cell lines. Whether increased FN1 expression is directly required for CTC migration, and the specific role of FN1’s regulation of integrin B1 (ITGB1) and SLUG (SNAI2) in CTC migration remains unclear. Here, for the first time, we report that the knockdown of FN1, ITGB1, or SLUG expression in CTCs leads to a significant decrease in CTC migration. Knocking down two or all three of these proteins simultaneously did not further inhibit migration. We observed a corresponding increase in CTC migration when recombinant FN1 was added to CTCs. This effect was significantly impeded by prior knockdown of ITGB1 or SLUG. Using knock down experiments and western blotting analysis, we confirmed FN1’s regulation of ITGB1 and SLUG to occur via two separate, independent pathways. Consequently, we can conclude that FN1-dependent enhanced migration of CTCs requires downstream signaling through either ITGB1 or SLUG and that FN1 regulation of ITGB1 and SLUG may have important implications for cancer progression and metastasis.
Collapse
Affiliation(s)
- Jeannette Huaman
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA;
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA
| | - Olorunseun O. Ogunwobi
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA;
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA
- Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA
- Correspondence:
| |
Collapse
|
18
|
Xiong X, Schober M, Tassone E, Khodadadi-Jamayran A, Sastre-Perona A, Zhou H, Tsirigos A, Shen S, Chang M, Melamed J, Ossowski L, Wilson EL. KLF4, A Gene Regulating Prostate Stem Cell Homeostasis, Is a Barrier to Malignant Progression and Predictor of Good Prognosis in Prostate Cancer. Cell Rep 2019; 25:3006-3020.e7. [PMID: 30540935 PMCID: PMC6405286 DOI: 10.1016/j.celrep.2018.11.065] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 11/07/2018] [Accepted: 11/15/2018] [Indexed: 12/18/2022] Open
Abstract
There is a considerable need to identify those individuals with prostate cancer who have indolent disease. We propose that
genes that control adult stem cell homeostasis in organs with slow turnover, such as the prostate, control cancer fate. One such
gene, KLF4, overexpressed in murine prostate stem cells, regulates their homeostasis, blocks malignant transformation, and
controls the self-renewal of tumor-initiating cells. KLF4 loss induces the molecular features of aggressive cancer and converts
PIN lesions to invasive sarcomatoid carcinomas; its re-expression in vivo reverses this process. Bioinformatic
analysis links these changes to human cancer. KLF4 and its downstream targets make up a gene signature that identifies indolent
tumors and predicts recurrence-free survival. This approach may improve prognosis and identify therapeutic targets for advanced
cancer. Available criteria for segregating prostate cancer patients into those requiring therapeutic intervention and those who can
be followed are inadequate. Xiong et al. show that KLF4 and its downstream targets make up a gene signature that identifies
indolent tumors. This approach may improve prognosis and identify therapeutic targets for advanced cancer.
Collapse
Affiliation(s)
- Xiaozhong Xiong
- Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA.
| | - Markus Schober
- Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA; Department of Dermatology, NYU School of Medicine, New York, NY 10016, USA
| | - Evelyne Tassone
- Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA
| | - Alireza Khodadadi-Jamayran
- Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, NYU School of Medicine, New York, NY 10016, USA
| | - Ana Sastre-Perona
- Department of Dermatology, NYU School of Medicine, New York, NY 10016, USA
| | - Hua Zhou
- Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, NYU School of Medicine, New York, NY 10016, USA
| | - Aristotelis Tsirigos
- Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, NYU School of Medicine, New York, NY 10016, USA
| | - Steven Shen
- Institute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA
| | - Miao Chang
- Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA
| | - Jonathan Melamed
- Department of Pathology, NYU School of Medicine, New York, NY 10016, USA
| | - Liliana Ossowski
- Department of Medicine, Mt. Sinai School of Medicine, New York, NY 10029, USA
| | - Elaine L Wilson
- Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA; Department of Urology, NYU School of Medicine, New York, NY 10016, USA.
| |
Collapse
|
19
|
Vickram AS, Samad HA, Latheef SK, Chakraborty S, Dhama K, Sridharan TB, Sundaram T, Gulothungan G. Human prostasomes an extracellular vesicle - Biomarkers for male infertility and prostrate cancer: The journey from identification to current knowledge. Int J Biol Macromol 2019; 146:946-958. [PMID: 31730983 DOI: 10.1016/j.ijbiomac.2019.09.218] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 09/24/2019] [Accepted: 09/25/2019] [Indexed: 02/07/2023]
Abstract
Extracellular vesicles (EVs) are gaining attention among the cell biologists and researchers over the last two decades. Prostasomes are considered to be (Evs) secreted by prostate epithelial cells into the semen during emission or ejaculation. Prostasomes contain various proteins required for immune regulation namely, amino and dipeptidyl peptidase; endopeptidase (neutral); decay accelerating factor; angiotensin-converting enzyme. Sperm cells need a few prerequisites in order to fertilize the egg. The role of prostasomes in enhancing the male fertility was reviewed extensively throughout the manuscript. Also, prostasomes have an immunosuppressive, immunomodulatory, antibacterial role in the female reproductive tract, and in some cases they can be used as immunocontraceptive agent to regulate the fertility status. This review will give insights to many active researchers in the field of prostasomal research and male infertility/fertility research. This review will open many unanswered mechanisms of prostasomes with respect to structure-function analysis, fatty acids patterns in diagnosis as well as prognosis of male infertility/fertility. More scientific reports are in need to support the mechanism of prostasomes and its role in immunomodulation. The development of prostasomes as a biomarker for the prostate cancer is still miserable with a lot of controversial results by various researchers.
Collapse
Affiliation(s)
- A S Vickram
- Saveetha School of Engineering, Department of Biotechnology, Saveetha Institute of Medical and Technical Sciences, Saveetha Nagar, Chennai 602 105, India.
| | - Hari Abdul Samad
- Division of Physiology and Climatology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243 122, Uttar Pradesh, India
| | - Shyma K Latheef
- Immunology Section, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh 243 122, India
| | - Sandip Chakraborty
- Department of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry, R.K. Nagar, West Tripura 799008, India
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, Uttar Pradesh, India
| | - T B Sridharan
- Department of Biotechnology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
| | - Thanigaivel Sundaram
- Saveetha School of Engineering, Department of Biomedical Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha Nagar, Chennai 602 105, India
| | - G Gulothungan
- Saveetha School of Engineering, Department of Biomedical Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha Nagar, Chennai 602 105, India
| |
Collapse
|
20
|
Paiva P, Sousa SF, Fernandes PA, João Ramos M. Human Fatty Acid Synthase: A Computational Study of the Transfer of the Acyl Moieties from MAT to the ACP Domain. ChemCatChem 2019. [DOI: 10.1002/cctc.201900548] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Pedro Paiva
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica Faculdade de CiênciasUniversidade do Porto Rua do Campo Alegre s/n 4169-007 Porto Portugal
| | - Sérgio F. Sousa
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica Faculdade de CiênciasUniversidade do Porto Rua do Campo Alegre s/n 4169-007 Porto Portugal
- UCIBIO@REQUIMTE, BioSIM – Departamento de Biomedicina Faculdade de MedicinaUniversidade do Porto Alameda Prof. Hernâni Monteiro 4200-319 Porto Portugal
| | - Pedro A. Fernandes
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica Faculdade de CiênciasUniversidade do Porto Rua do Campo Alegre s/n 4169-007 Porto Portugal
| | - Maria João Ramos
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica Faculdade de CiênciasUniversidade do Porto Rua do Campo Alegre s/n 4169-007 Porto Portugal
| |
Collapse
|
21
|
Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells 2019; 8:cells8060618. [PMID: 31226820 PMCID: PMC6627780 DOI: 10.3390/cells8060618] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/18/2019] [Accepted: 06/19/2019] [Indexed: 12/12/2022] Open
Abstract
Metastasis is the leading cause of cancer death worldwide. Circulating tumor cells (CTCs) are a critical step in the metastatic cascade and a good tool to study this process. We isolated CTCs from a syngeneic mouse model of hepatocellular carcinoma (HCC) and a human xenograft mouse model of castration-resistant prostate cancer (CRPC). From these models, novel primary tumor and CTC cell lines were established. CTCs exhibited greater migration than primary tumor-derived cells, as well as epithelial-to-mesenchymal transition (EMT), as observed from decreased E-cadherin and increased SLUG and fibronectin expression. Additionally, when fibronectin was knocked down in CTCs, integrin B1 and SLUG were decreased, indicating regulation of these molecules by fibronectin. Investigation of cell surface molecules and secreted cytokines conferring immunomodulatory advantage to CTCs revealed decreased major histocompatibility complex class I (MHCI) expression and decreased endostatin, C-X-C motif chemokine 5 (CXCL5), and proliferin secretion by CTCs. Taken together, these findings indicate that CTCs exhibit distinct characteristics from primary tumor-derived cells. Furthermore, CTCs demonstrate enhanced migration in part through fibronectin regulation of integrin B1 and SLUG. Further study of CTC biology will likely uncover additional important mechanisms of cancer metastasis.
Collapse
Affiliation(s)
- Jeannette Huaman
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
| | - Michelle Naidoo
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
| | - Xingxing Zang
- Departments of Microbiology and Immunology, and Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
| | - Olorunseun O Ogunwobi
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
- Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA.
| |
Collapse
|
22
|
Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. World J Urol 2019; 38:637-645. [DOI: 10.1007/s00345-019-02651-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Accepted: 01/22/2019] [Indexed: 12/20/2022] Open
|
23
|
Parra JPRLL, Crulhas BP, Basso CR, Delella FK, Castro GR, Pedrosa VA. Using an Electrochemical Aptasensor to Early Detect Prostate Specific and Free Prostate Specific Antigens Released by Cancer Cells. ELECTROANAL 2018. [DOI: 10.1002/elan.201800558] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
| | - Bruno P. Crulhas
- Chemistry and Biochemistry Department, Institute of BioscienceUNESP Botucatu, SP Brazil
| | - Caroline R. Basso
- Chemistry and Biochemistry Department, Institute of BioscienceUNESP Botucatu, SP Brazil
| | - Flávia K. Delella
- Chemistry and Biochemistry Department, Institute of BioscienceUNESP Botucatu, SP Brazil
| | - Gustavo R. Castro
- Chemistry and Biochemistry Department, Institute of BioscienceUNESP Botucatu, SP Brazil
| | - Valber A. Pedrosa
- Chemistry and Biochemistry Department, Institute of BioscienceUNESP Botucatu, SP Brazil
| |
Collapse
|
24
|
Pagoto A, Tripepi M, Stefania R, Lanzardo S, Livio Longo D, Garello F, Porpiglia F, Manfredi M, Aime S, Terreno E. An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma. Magn Reson Med 2018; 81:1935-1946. [DOI: 10.1002/mrm.27494] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 07/23/2018] [Accepted: 07/23/2018] [Indexed: 01/10/2023]
Affiliation(s)
- Amerigo Pagoto
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Martina Tripepi
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Rachele Stefania
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Stefania Lanzardo
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Dario Livio Longo
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Francesca Garello
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| | - Francesco Porpiglia
- Division of Urology University of Torino, San Luigi Gonzaga Hospital Orbassano, Torino Italy
| | - Matteo Manfredi
- Division of Urology University of Torino, San Luigi Gonzaga Hospital Orbassano, Torino Italy
| | - Silvio Aime
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
- IBB‐CNR Sede Secondaria c/o MBC Torino Italy
| | - Enzo Terreno
- Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
| |
Collapse
|
25
|
Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. CONTRAST MEDIA & MOLECULAR IMAGING 2018; 2018:3181258. [PMID: 30327584 PMCID: PMC6169212 DOI: 10.1155/2018/3181258] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 07/22/2018] [Indexed: 02/08/2023]
Abstract
Background and Purpose Although several methods have been developed to predict the outcome of patients with prostate cancer, early diagnosis of individual patient remains challenging. The aim of the present study was to correlate tumor perfusion parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and clinical prognostic factors and further to explore the diagnostic value of DCE-MRI parameters in early stage prostate cancer. Patients and Methods Sixty-two newly diagnosed patients with histologically proven prostate adenocarcinoma were enrolled in our prospective study. Transrectal ultrasound-guided biopsy (12 cores, 6 on each lobe) was performed in each patient. Pathology was reviewed and graded according to the Gleason system. DCE-MRI was performed and analyzed using a two-compartmental model; quantitative parameters including volume transfer constant (Ktrans), reflux constant (Kep), and initial area under curve (iAUC) were calculated from the tumors and correlated with prostate-specific antigen (PSA), Gleason score, and clinical stage. Results Ktrans (0.11 ± 0.02 min−1 versus 0.16 ± 0.06 min−1; p < 0.05), Kep (0.38 ± 0.08 min−1 versus 0.60 ± 0.23 min−1; p < 0.01), and iAUC (14.33 ± 2.66 mmoL/L/min versus 17.40 ± 5.97 mmoL/L/min; p < 0.05) were all lower in the clinical stage T1c tumors (tumor number, n=11) than that of tumors in clinical stage T2 (n=58). Serum PSA correlated with both tumor Ktrans (r=0.304, p < 0.05) and iAUC (r=0.258, p < 0.05). Conclusions Our study has confirmed that DCE-MRI is a promising biomarker that reflects the microcirculation of prostate cancer. DCE-MRI in combination with clinical prognostic factors may provide an effective new tool for the basis of early diagnosis and treatment decisions.
Collapse
|
26
|
Clos-Garcia M, Loizaga-Iriarte A, Zuñiga-Garcia P, Sánchez-Mosquera P, Rosa Cortazar A, González E, Torrano V, Alonso C, Pérez-Cormenzana M, Ugalde-Olano A, Lacasa-Viscasillas I, Castro A, Royo F, Unda M, Carracedo A, Falcón-Pérez JM. Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. J Extracell Vesicles 2018; 7:1470442. [PMID: 29760869 PMCID: PMC5944373 DOI: 10.1080/20013078.2018.1470442] [Citation(s) in RCA: 104] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 04/17/2018] [Indexed: 02/06/2023] Open
Abstract
Urine contains extracellular vesicles (EVs) that concentrate molecules and protect them from degradation. Thus, isolation and characterisation of urinary EVs could increase the efficiency of biomarker discovery. We have previously identified proteins and RNAs with differential abundance in urinary EVs from prostate cancer (PCa) patients compared to benign prostate hyperplasia (BPH). Here, we focused on the analysis of the metabolites contained in urinary EVs collected from patients with PCa and BPH. Targeted metabolomics analysis of EVs was performed by ultra-high-performance liquid chromatography–mass spectrometry. The correlation between metabolites and clinical parameters was studied, and metabolites with differential abundance in PCa urinary EVs were detected and mapped into cellular pathways. We detected 248 metabolites belonging to different chemical families including amino acids and various lipid species. Among these metabolites, 76 exhibited significant differential abundance between PCa and BPH. Interestingly, urine EVs recapitulated many of the metabolic alterations reported in PCa, including phosphathidylcholines, acyl carnitines, citrate and kynurenine. Importantly, we found elevated levels of the steroid hormone, 3beta-hydroxyandros-5-en-17-one-3-sulphate (dehydroepiandrosterone sulphate) in PCa urinary EVs, in line with the potential elevation of androgen synthesis in this type of cancer. This work supports urinary EVs as a non-invasive source to infer metabolic changes in PCa.
Collapse
Affiliation(s)
| | - Ana Loizaga-Iriarte
- Department of Urology, Basurto University Hospital, Bilbao, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
| | | | | | - Ana Rosa Cortazar
- CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
| | | | - Verónica Torrano
- CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
| | | | | | - Aitziber Ugalde-Olano
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).,Department of Pathology, Basurto University Hospital, Bilbao, Spain
| | - Isabel Lacasa-Viscasillas
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).,Department of Pathology, Basurto University Hospital, Bilbao, Spain
| | | | - Felix Royo
- CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)
| | - Miguel Unda
- Department of Urology, Basurto University Hospital, Bilbao, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
| | - Arkaitz Carracedo
- CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).,Ikerbasque, Basque foundation for science, Bilbao, Spain.,Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bilbao, Spain
| | - Juan M Falcón-Pérez
- CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD).,Ikerbasque, Basque foundation for science, Bilbao, Spain
| |
Collapse
|
27
|
Emerging proteomics biomarkers and prostate cancer burden in Africa. Oncotarget 2018; 8:37991-38007. [PMID: 28388542 PMCID: PMC5514967 DOI: 10.18632/oncotarget.16568] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 02/27/2017] [Indexed: 12/25/2022] Open
Abstract
Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.
Collapse
|
28
|
Paiva P, Sousa SF, Ramos MJ, Fernandes PA. Understanding the Catalytic Machinery and the Reaction Pathway of the Malonyl-Acetyl Transferase Domain of Human Fatty Acid Synthase. ACS Catal 2018. [DOI: 10.1021/acscatal.8b00577] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Pedro Paiva
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal
| | - Sérgio F. Sousa
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal
| | - Maria J. Ramos
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal
| | - Pedro A. Fernandes
- UCIBIO@REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal
| |
Collapse
|
29
|
Haldrup C, Pedersen AL, Øgaard N, Strand SH, Høyer S, Borre M, Ørntoft TF, Sørensen KD. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. Mol Oncol 2018; 12:545-560. [PMID: 29465788 PMCID: PMC5891052 DOI: 10.1002/1878-0261.12183] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 10/17/2017] [Accepted: 02/14/2018] [Indexed: 01/04/2023] Open
Abstract
Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, leading to overdiagnosis and overtreatment. Aberrant promoter hypermethylation of specific genes has been suggested as novel candidate biomarkers for PC that may improve diagnosis and prognosis. We here analyzed ST6GALNAC3 and ZNF660 promoter methylation in prostate tissues, and ST6GALNAC3,ZNF660,CCDC181, and HAPLN3 promoter methylation in liquid biopsies. First, using four independent patient sample sets, including a total of 110 nonmalignant (NM) and 705 PC tissue samples, analyzed by methylation‐specific qPCR or methylation array, we found that hypermethylation of ST6GALNAC3 and ZNF660 was highly cancer‐specific with areas under the curve (AUC) of receiver operating characteristic (ROC) curve analysis of 0.917–0.995 and 0.846–0.903, respectively. Furthermore, ZNF660 hypermethylation was significantly associated with biochemical recurrence in two radical prostatectomy (RP) cohorts of 158 and 392 patients and remained significant also in the subsets of patients with Gleason score ≤7 (univariate Cox regression and log‐rank tests, P < 0.05), suggesting that ZNF660 methylation analysis can potentially help to stratify low‐/intermediate‐grade PCs into indolent vs. more aggressive subtypes. Notably, ZNF660 hypermethylation was also significantly associated with poor overall and PC‐specific survival in the RP cohort (n = 158) with long clinical follow‐up available. Moreover, as proof of principle, we successfully detected highly PC‐specific hypermethylated circulating tumor DNA (ctDNA) for ST6GALNAC3,ZNF660,HAPLN3, and CCDC181 in liquid biopsies (serum) from 27 patients with PC vs. 10 patients with BPH, using droplet digital methylation‐specific PCR analysis. Finally, we generated a three‐gene (ST6GALNAC3/CCDC181/HAPLN3) ctDNA hypermethylation model, which detected PC with 100% specificity and 67% sensitivity. In conclusion, we here for the first time demonstrate diagnostic biomarker potential of ST6GALNAC3 and ZNF660 methylation, as well as prognostic biomarker potential of ZNF660. Furthermore, we show that hypermethylation of four genes can be detected in ctDNA in liquid biopsies (serum) from patients with PC.
Collapse
Affiliation(s)
- Christa Haldrup
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| | - Anne L Pedersen
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| | - Nadia Øgaard
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| | - Siri H Strand
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| | - Søren Høyer
- Department of Histopathology, Aarhus University Hospital, Denmark
| | - Michael Borre
- Department of Urology, Aarhus University Hospital, Denmark
| | - Torben F Ørntoft
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| | - Karina D Sørensen
- Department of Molecular Medicine, Aarhus University Hospital, Denmark
| |
Collapse
|
30
|
The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis 2017; 21:22-36. [PMID: 29282359 DOI: 10.1038/s41391-017-0023-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 10/11/2017] [Accepted: 11/02/2017] [Indexed: 01/07/2023]
Abstract
BACKGROUND With continuous progress over the past few decades in understanding diagnosis, treatment, and genetics, much has been learned about the prostate cancer-diagnosed genome. METHODS A comprehensive MEDLINE® and Google scholar literature search was conducted using keyword variations relating to the genetics of prostate cancer such as chromosomal alterations, androgen receptor, castration-resistant, inheritance, polymorphisms, oncogenes, metastasis, biomarkers, and immunotherapy. RESULTS Traditionally, androgen receptors (AR) have been the focus of research. Recently, identification of recurrent chromosomal alterations that lead to either multiplication of regions (gain-of-function) or deletion of regions (loss-of-function) has opened the door to greater genetic accessibility. These chromosomal aberrations lead to variation in copy number and gene expression. Some of these chromosomal alterations are inherited, while others undergo somatic mutations during disease progression. Inherited gene mutations that make one susceptible to prostate cancer have been identified with familial-linked studies. Somatic genes that progress tumorigenesis have also been identified. Research on the molecular biology of prostate cancer has characterized these genes into tumor suppressor genes or oncogenes. Additionally, genome-wide assay studies have identified many high-risk single-nucleotide polymorphisms recurrent throughout the prostate cancer-diagnosed genome. Castration-resistant prostate cancer is the most aggressive form of prostate cancer, and its research has elucidated many types of mutations associated with AR itself, including enhanced expression and amplification, point mutations, and alternative splicing. Understanding the molecular biology of prostate cancer has permitted more accurate identification using advanced biomarkers and therapy for aggressive forms using immunotherapy. CONCLUSIONS An age-related disease, prostate cancer commands profound attention. With increasing life expectancy and the continuous pursuit of it, prostate cancer is a powerful obstacle best defeated using targeted therapies specifically designed for the unique molecular profile of the malignancy.
Collapse
|
31
|
Current advances and future visions on bioelectronic immunosensing for prostate-specific antigen. Biosens Bioelectron 2017; 98:267-284. [DOI: 10.1016/j.bios.2017.06.049] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 06/13/2017] [Accepted: 06/25/2017] [Indexed: 01/28/2023]
|
32
|
Goč S, Jankovič M. Human Serum Low Molecular Mass Prostate-specific Antigen As Biomarker. J Med Biochem 2017; 36:322-330. [PMID: 30581329 PMCID: PMC6294081 DOI: 10.1515/jomb-2017-0024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 04/27/2017] [Indexed: 11/15/2022] Open
Abstract
Background Prostate-specific antigen (PSA) is a glycoprotein tumor marker known to exist as numerous glycospecies. Investigations on its glycobiochemical properties aimed at their use in the preparation of adjuncts in determining PSA concentration for clinical purposes have accumulated a lot of data on its structural properties. In this study, we reconsidered unexplored ubiquitously present low molecular mass species of PSA regarding to molecular mass, origin and pathophysiological source specificity in order to evaluate them as biomarkers. Methods Data on low molecular mass PSA-immunoreactive species from sera of subjects with prostate cancer (PCa), benign prostatic hyperplasia (BPH), breast cancer (BCa), and urine of healthy males obtained by on-chip immunoaffinity chromatography combined with mass spectrometry were analyzed. Results The results obtained indicated PSA species common to BCa, PCa, and BPH at 12-13 kDa, 17-19 kDa and 21-24 kDa. The striking difference in predominant frequencies made the profile characteristic in each examined pathophysiological condition. On the other hand, paired groups of prostatic and extraprostatic PSA contained rare species with small differences among groups concerning individual species. Low molecular mass PSA also included rare species unique for each group of samples. Conclusion The results obtained revealed that uniformity of low molecular mass PSA-immunoreactive species in sera prevails over diversity related to cancer and non-cancer conditions, but at the same time some of them are molecules with biomarker potential for BPH detection.
Collapse
Affiliation(s)
- Sanja Goč
- Department for Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia
| | - Miroslava Jankovič
- Department for Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia
| |
Collapse
|
33
|
Crulhas BP, Karpik AE, Delella FK, Castro GR, Pedrosa VA. Electrochemical aptamer-based biosensor developed to monitor PSA and VEGF released by prostate cancer cells. Anal Bioanal Chem 2017; 409:6771-6780. [PMID: 29032455 DOI: 10.1007/s00216-017-0630-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Revised: 08/30/2017] [Accepted: 09/07/2017] [Indexed: 11/21/2022]
Abstract
Early prostate cancer (PCa) diagnostic is crucial to enhance patient survival rates; besides, non-invasive platforms have been developed worldwide in order to precisely detect PCa biomarkers. Therefore, the aim of the present study is to develop a new aptamer-based biosensor through the self-assembling of thiolated aptamers for PSA and VEGF on the top of gold electrodes. This biosensor was tested in three prostate cell lines (RWPE-1, LNCaP and PC3). The results evidenced a stable and sensitive sensor presenting wide linear detection ranges (0.08-100 ng/mL for PSA and 0.15 ng-100 ng/mL for VEGF). Therefore, the aptasensor was able to detect the patterns of PSA and VEGF released in vitro by PCa cells, which gave new insights about the prostate cancer protein dynamics. Thus, it could be used as a non-invasive PCa clinical diagnosis instrument in the near future. Graphical Abstract Overview of the experimental design applied to the aptamer-based electrochemical sensor self-assembled on the thiolated hairpin structure. A filter membrane was added on top of working electrode to provide the cell-attachment surface after aptamer incubation, without compromising the aptamer layer. The pore membrane allowed target proteins to pass to the aptamer surface; the MCH backfilling avoided unspecific protein binding to the gold electrode surface.
Collapse
Affiliation(s)
- Bruno P Crulhas
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP-Botucatu, Distrito de Rubiao Jr, 18618-000 Botucatu, São Paulo, 18618-000, Brazil
| | - Agnieszka E Karpik
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP-Botucatu, Distrito de Rubiao Jr, 18618-000 Botucatu, São Paulo, 18618-000, Brazil
| | - Flávia K Delella
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP-Botucatu, Distrito de Rubiao Jr, 18618-000 Botucatu, São Paulo, 18618-000, Brazil
| | - Gustavo R Castro
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP-Botucatu, Distrito de Rubiao Jr, 18618-000 Botucatu, São Paulo, 18618-000, Brazil
| | - Valber A Pedrosa
- Department of Chemistry and Biochemistry, Institute of Bioscience, UNESP-Botucatu, Distrito de Rubiao Jr, 18618-000 Botucatu, São Paulo, 18618-000, Brazil.
| |
Collapse
|
34
|
Mousavi MF, Amiri M, Noori A, Khoshfetrat SM. A Prostate Specific Antigen Immunosensor Based on Biotinylated-Antibody/Cyclodextrin Inclusion Complex: Fabrication and Electrochemical Studies. ELECTROANAL 2017. [DOI: 10.1002/elan.201700363] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Mir F. Mousavi
- Department of Chemistry; Tarbiat Modares University; Tehran 14115-175 Iran, (Mir F. Mousavi)
| | - Masoud Amiri
- Department of Chemistry; Tarbiat Modares University; Tehran 14115-175 Iran, (Mir F. Mousavi)
| | - Abolhassan Noori
- Department of Chemistry; Tarbiat Modares University; Tehran 14115-175 Iran, (Mir F. Mousavi)
| | | |
Collapse
|
35
|
Adubeiro N, Nogueira ML, Nunes RG, Ferreira HA, Ribeiro E, La Fuente JMF. Apparent diffusion coefficient in the analysis of prostate cancer: determination of optimal b-value pair to differentiate normal from malignant tissue. Clin Imaging 2017; 47:90-95. [PMID: 28917137 DOI: 10.1016/j.clinimag.2017.09.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 09/04/2017] [Accepted: 09/06/2017] [Indexed: 12/16/2022]
Abstract
PURPOSE Determining optimal b-value pair for differentiation between normal and prostate cancer (PCa) tissues. METHODS Forty-three patients with diagnosis or PCa symptoms were included. Apparent diffusion coefficient (ADC) was estimated using minimum and maximum b-values of 0, 50, 100, 150, 200, 500s/mm2 and 500, 800, 1100, 1400, 1700 and 2000s/mm2, respectively. Diagnostic performances were evaluated when Area-under-the-curve (AUC)>95%. RESULTS 15 of the 35 b-values pair surpassed this AUC threshold. The pair (50, 2000s/mm2) provided the highest AUC (96%) with ADC cutoff 0.89×10-3mm2/s, sensitivity 95.5%, specificity 93.2% and accuracy 94.4%. CONCLUSIONS The best b-value pair was b=50, 2000s/mm2.
Collapse
Affiliation(s)
- Nuno Adubeiro
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; Department of Radiology, School of Health of Porto/Polytechnic Institute of Porto (ESS/IPP), Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal.
| | - Maria Luísa Nogueira
- Department of Radiology, School of Health of Porto/Polytechnic Institute of Porto (ESS/IPP), Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal
| | - Rita G Nunes
- Institute for Systems and Robotics and Department of Bioengineering, LARSyS, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal
| | - Hugo Alexandre Ferreira
- Institute of Biophysics and Biomedical Engineering (IBEB), Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisboa, Portugal
| | - Eduardo Ribeiro
- Department of Radiology, MRI Unit, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Department of Radiology, School of Health of Porto (ESS), Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal
| | - José Maria Ferreira La Fuente
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.; Department of Urology, Center Hospitalar Porto (CHP), Largo Prof. Abel Salazar, 4099-001 Porto, Portugal
| |
Collapse
|
36
|
Akizhanova M, Iskakova EE, Kim V, Wang X, Kogay R, Turebayeva A, Sun Q, Zheng T, Wu S, Miao L, Xie Y. PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis. J Cancer 2017; 8:1223-1228. [PMID: 28607597 PMCID: PMC5463437 DOI: 10.7150/jca.18012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Accepted: 12/23/2016] [Indexed: 12/03/2022] Open
Abstract
Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68% of patients have cancer with Gleason score ranged 6-8 and 65.77% of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.
Collapse
Affiliation(s)
- Mariyam Akizhanova
- Department of Biology, School of Science and Technology, Nazarbayev University, Astana, 010000, Republic of Kazakhstan
| | - Elzira E Iskakova
- Module of Pathological Anatomy, Kazakh National Medical University, Almaty, 050000, Republic of Kazakhstan
| | - Valdemir Kim
- Department of Biology, School of Science and Technology, Nazarbayev University, Astana, 010000, Republic of Kazakhstan
| | - Xiao Wang
- Shandong Analysis and Test Center, Shandong Academy of Sciences, 19 keyuan Street, Jinan, 250014, P.R. China
| | - Roman Kogay
- Department of Biology, School of Science and Technology, Nazarbayev University, Astana, 010000, Republic of Kazakhstan
| | - Aiym Turebayeva
- Department of Biology, School of Science and Technology, Nazarbayev University, Astana, 010000, Republic of Kazakhstan
| | - Qinglei Sun
- Shandong Analysis and Test Center, Shandong Academy of Sciences, 19 keyuan Street, Jinan, 250014, P.R. China
| | - Ting Zheng
- Shandong Analysis and Test Center, Shandong Academy of Sciences, 19 keyuan Street, Jinan, 250014, P.R. China
| | - Shenghui Wu
- Department of Epidemiology & Biostatistics, University of Texas Health at San Antonio Laredo Campus, Laredo, TX 78041, USA
| | - Lixia Miao
- College of Basic Medicine, Wuhan University, Wuhan, 430071, P.R. China
| | - Yingqiu Xie
- Department of Biology, School of Science and Technology, Nazarbayev University, Astana, 010000, Republic of Kazakhstan
| |
Collapse
|